Capecitabine for Cancer of Colon
Phase-Based Progress Estimates
Effectiveness
Safety
Saint Francis Cancer Center, Colorado Springs, CO
Cancer of Colon+2 More
Capecitabine - DrugEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
This trial tests how well ctDNA testing in the blood predicts treatment for patients with stage IIA colon cancer after surgery. ctDNA are circulating tumor cells that are shed by tumors into the blood. Finding ctDNA in the blood means that there is very likely some small amounts of cancer that remain after surgery. However, this cancer, if detected, cannot be found on other tests usually used to find cancer, as it is too small. Testing for ctDNA levels may help identify patients with colon cancer after surgery who do benefit, and those who do not benefit, from receiving chemotherapy. The primary treatment in this trial is fluorouracil, which is used to treat cancer of the colon. This treatment has previously been approved by the FDA for a different condition. There will be no patients in this trial who receive a placebo.
Eligible Conditions
- Cancer of Colon
- Adenocarcinoma
- Malignant Neoplasms
Treatment Effectiveness
Effectiveness Progress
Other trials for Cancer of Colon
Study Objectives
2 Primary · 5 Secondary · Reporting Duration: Up to 3 years
Month 6
Clearance of circulating tumor deoxyribonucleic acid (ctDNA) (to undetectable levels) for the "baseline ctDNA detected" patient subset (Phase II)
Year 3
Recurrence-free survival (RFS) the "baseline ctDNA detected" patient subset (Phase III)
Up to 3 years
Compliance with adjuvant chemotherapy and/or active surveillance
Cost effectiveness of the use of ctDNA versus standard of care
Genomic profiles
Incidence (presence or absence) of ctDNA in blood following resection of stage II colon cancer
Overall survival (OS)
Quantitative ctDNA levels
RFS
Time to recurrence (TTR)
Trial Safety
Safety Progress
This is further along than 68% of similar trials
Other trials for Cancer of Colon
Trial Design
2 Treatment Groups
Arm I (blood stored and tested for ctDNA later)
1 of 2
Arm II (blood tested for ctDNA at baseline)
1 of 2
Active Control
Experimental Treatment
1408 Total Participants · 2 Treatment Groups
Primary Treatment: Capecitabine · No Placebo Group · Phase 2 & 3
Arm II (blood tested for ctDNA at baseline)Experimental Group · 6 Interventions: Leucovorin Calcium, Leucovorin, Capecitabine, Fluorouracil, Patient Observation, Oxaliplatin · Intervention Types: Drug, Drug, Drug, Drug, Other, Drug
Arm I (blood stored and tested for ctDNA later)
Other
ActiveComparator Group · 1 Intervention: Patient Observation · Intervention Types: OtherTreatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Calcium
Not yet FDA approved
Leucovorin
FDA approved
Capecitabine
FDA approved
Fluorouracil
FDA approved
Oxaliplatin
FDA approved
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 3 years
Closest Location: Saint Francis Cancer Center · Colorado Springs, CO
2016First Recorded Clinical Trial
0 TrialsResearching Cancer of Colon
46 CompletedClinical Trials
Who is running the clinical trial?
National Cancer Institute (NCI)NIH
12,930 Previous Clinical Trials
41,292,379 Total Patients Enrolled
1 Trials studying Cancer of Colon
500 Patients Enrolled for Cancer of Colon
NRG OncologyLead Sponsor
215 Previous Clinical Trials
92,078 Total Patients Enrolled
Van K MorrisPrincipal InvestigatorNRG Oncology
3 Previous Clinical Trials
196 Total Patients Enrolled
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:Appropriate for active surveillance (i.e.
The tissue must be available for molecular diagnostics and confirmatory profiling.
Platelet count must be > 100,000/mm^3 (within 28 days before randomization).
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Top Oncology Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments